Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC

Cancer Immunology, Immunotherapy

Volumn 60, Issue 5, 2011, Pages 639-648

  Battke, Christina ^a   Ruiss, Romana ^b   Welsch, Ulrich ^b   Wimberger, Pauline ^c   Lang, Stephan ^c   Jochum, Simon ^a   Zeidler, Reinhard ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

ADCC; Exosomes; Immune escape; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GANGLIOSIDE GM1; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR EXOSOME;

ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOSOMES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MICROSCOPY, ELECTRON; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TUMOR ESCAPE;

EID: 79955548092     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0979-5     Document Type: Article

References (53)

1. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 267 296 17134371 1:CAS:528:DC%2BD2sXltlagu7c%3D (Pubitemid 46697910)
2. SJ Antonia M Extermann RA Flavell 1998 Immunologic nonresponsiveness to tumors Crit Rev Oncog 9 35 41 9754446 1:STN:280:DyaK1cvisFCitQ%3D%3D (Pubitemid 28436456)
3. G Willimsky T Blankenstein 2005 Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance Nature 437 141 146 16136144 1:CAS:528:DC%2BD2MXpslalsLg%3D (Pubitemid 41613441)
4. A Clayton JP Mitchell J Court MD Mason Z Tabi 2007 Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2 Cancer Res 67 7458 7466 17671216 1:CAS:528:DC%2BD2sXosVemtLc%3D (Pubitemid 47214451)
5. R Valenti V Huber P Filipazzi L Pilla G Sovena A Villa A Corbelli S Fais G Parmiani L Rivoltini 2006 Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes Cancer Res 66 9290 9298 16982774 1:CAS:528:DC%2BD28Xps1ahsrg%3D (Pubitemid 44521151)
6. JW Kim E Wieckowski DD Taylor TE Reichert S Watkins TL Whiteside 2005 Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes Clin Cancer Res 11 1010 1020 15709166 1:CAS:528:DC%2BD2MXht1ynsb0%3D (Pubitemid 40175748)
7. DD Taylor C Gercel-Taylor KS Lyons J Stanson TL Whiteside 2003 T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors Clin Cancer Res 9 5113 5119 14613988 1:CAS:528:DC%2BD3sXovVOgtbo%3D (Pubitemid 37413559)
8. C Liu S Yu K Zinn J Wang L Zhang Y Jia JC Kappes S Barnes RP Kimberly WE Grizzle HG Zhang 2006 Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function J Immunol 176 1375 1385 16424164 1:CAS:528:DC%2BD28XlsFyiug%3D%3D (Pubitemid 43134279)
9. A Clayton JP Mitchell J Court S Linnane MD Mason Z Tabi 2008 Human tumor-derived exosomes down-modulate NKG2D expression J Immunol 180 7249 7258 18490724 1:CAS:528:DC%2BD1cXmtVantbo%3D
10. J Skog T Wurdinger S van Rijn DH Meijer L Gainche M Sena-Esteves WTJ Curry BS Carter AM Krichevsky XO Breakefield 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat Cell Biol 10 1470 1476 19011622 1:CAS:528:DC%2BD1cXhsVentbfI
11. S Runz S Keller C Rupp A Stoeck Y Issa D Koensgen A Mustea J Sehouli G Kristiansen P Altevogt 2007 Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM Gynecol Oncol 107 563 571 17900673 1:CAS:528:DC%2BD2sXhtlyrt7vE (Pubitemid 350160873)
12. A Trojan A Tun-Kyi B Odermatt FO Nestle RA Stahel 2002 Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors Lung Cancer 36 151 158 11955649 (Pubitemid 34296557)
13. G Bioley C Jandus S Tuyaerts D Rimoldi WW Kwok DE Speiser JM Tiercy K Thielemans JC Cerottini P Romero 2006 Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers J Immunol 177 6769 6779 17082590 1:CAS:528:DC%2BD28XhtFGrtrzN (Pubitemid 44715041)
14. R Mears RA Craven S Hanrahan N Totty C Upton SL Young P Patel PJ Selby RE Banks 2004 Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry Proteomics 4 4019 4031 15478216 1:CAS:528:DC%2BD2cXhtFarsb%2FK (Pubitemid 39657475)
15. F Andre NE Schartz M Movassagh C Flament P Pautier P Morice C Pomel C Lhomme B Escudier T Le Chevalier T Tursz S Amigorena G Raposo E Angevin L Zitvogel 2002 Malignant effusions and immunogenic tumour-derived exosomes Lancet 360 295 305 12147373 1:CAS:528:DC%2BD38XlvVSmsL4%3D (Pubitemid 34874721)
16. K Kono Y Rongcun J Charo F Ichihara E Celis A Sette E Appella T Sekikawa Y Matsumoto R Kiessling 1998 Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes Int J Cancer 78 202 208 9754653 1:CAS:528:DyaK1cXmsVals7c%3D (Pubitemid 28443178)
17. M Reuschenbach M von Knebel Doeberitz N Wentzensen 2009 A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 58 1535 1544 19562338 1:CAS:528:DC%2BD1MXptVentr4%3D
18. Taylor DD, Gercel-Taylor C, Parker LP (2009) Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol, Oncol
19. J Baselga SM Swain 2009 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 463 475 19536107 1:CAS:528: DC%2BD1MXnsVagtbs%3D
20. E Tagliabue A Balsari M Campiglio SM Pupa 2010 HER2 as a target for breast cancer therapy Expert Opin Biol Ther 10 711 724 20214497 1:CAS:528:DC%2BC3cXksFCgtr8%3D
21. ML Disis SM Pupa JR Gralow R Dittadi S Menard MA Cheever 1997 High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer J Clin Oncol 15 3363 3367 9363867 1:STN:280: DyaK1c%2FivVCqtQ%3D%3D (Pubitemid 27485856)
22. RB Montgomery E Makary K Schiffman V Goodell ML Disis 2005 Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase Cancer Res 65 650 656 15695410 1:CAS:528:DC%2BD2MXns1OisQ%3D%3D
23. RL Ward NJ Hawkins D Coomber ML Disis 1999 Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer Hum Immunol 60 510 515 10408800 1:STN:280:DyaK1MzjsFartw%3D%3D (Pubitemid 29296307)
24. Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P (2010) EpCAM-autoantibody levels in the course of disease of ovarian cancer patients. Med, Oncol
25. JH Kim D Herlyn KK Wong DC Park JO Schorge KH Lu SJ Skates DW Cramer RS Berkowitz SC Mok 2003 Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer Clin Cancer Res 9 4782 4791 14581349 1:CAS:528:DC%2BD3sXosVGjsb0%3D (Pubitemid 37323281)
26. A de Gassart C Geminard B Fevrier G Raposo M Vidal 2003 Lipid raft-associated protein sorting in exosomes Blood 102 4336 4344 12881314 (Pubitemid 37494093)
27. G Raposo HW Nijman W Stoorvogel R Liejendekker CV Harding CJ Melief HJ Geuze 1996 B lymphocytes secrete antigen-presenting vesicles J Exp Med 183 1161 1172 8642258 1:CAS:528:DyaK28XhvV2qsLs%3D (Pubitemid 26113979)
28. R Valenti V Huber M Iero P Filipazzi G Parmiani L Rivoltini 2007 Tumor-released microvesicles as vehicles of immunosuppression Cancer Res 67 2912 2915 17409393 1:CAS:528:DC%2BD2sXksVGlt7o%3D (Pubitemid 46724823)
29. M Iero R Valenti V Huber P Filipazzi G Parmiani S Fais L Rivoltini 2008 Tumour-released exosomes and their implications in cancer immunity Cell Death Differ 15 80 88 17932500 1:CAS:528:DC%2BD2sXhsVegur3J (Pubitemid 350286175)
30. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446 10742152 1:CAS:528:DC%2BD3cXisVOru7Y%3D (Pubitemid 30208162)
31. TK Park SN Kim 1989 Cell-mediated immunity in patients with invasive carcinoma of the cervix Yonsei Med J 30 164 172 2800566 1:STN:280: DyaK3c%2FitFGisw%3D%3D
32. H Matsuzaki T Kagimoto T Oda F Kawano K Takatsuki 1985 Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma Jpn J Clin Oncol 15 611 617 4094094 1:STN:280:DyaL287ksVClsA%3D%3D
33. F Dallegri A Ballestrero L Ottonello F Patrone 1989 Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients Clin Exp Immunol 77 58 61 2766579 1:STN:280:DyaL1MzlsFCqsg%3D%3D (Pubitemid 19198813)
34. J Baselga J Albanell MA Molina J Arribas 2001 Mechanism of action of trastuzumab and scientific update Semin Oncol 28 4 11 11706390 1:CAS:528:DC%2BD3MXpt1Wgu74%3D (Pubitemid 33065104)
35. Y Katsumi Y Kuwahara S Tamura K Kikuchi O Otabe K Tsuchiya T Iehara H Kuroda H Hosoi T Sugimoto 2008 Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity Clin Cancer Res 14 1192 1199 18281554 1:CAS:528:DC%2BD1cXhvF2nsbY%3D (Pubitemid 351302568)
36. NL Spector KL Blackwell 2009 Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 5838 5847 19884552 1:CAS:528:DC%2BC3cXhtVWitro%3D
37. C Chen J Skog CH Hsu RT Lessard L Balaj T Wurdinger BS Carter XO Breakefield M Toner D Irimia 2010 Microfluidic isolation and transcriptome analysis of serum microvesicles Lab Chip 10 505 511 20126692 1:CAS:528:DC%2BC3cXhtlGiu78%3D
38. S Keller AK Konig F Marme S Runz S Wolterink D Koensgen A Mustea J Sehouli P Altevogt 2009 Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes Cancer Lett 278 73 81 19188015 1:CAS:528:DC%2BD1MXktFajs78%3D
39. H Lu V Goodell ML Disis 2008 Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer J Proteome Res 7 1388 1394 18311901 1:CAS:528:DC%2BD1cXisVylt70%3D
40. DG McNeel LD Nguyen BE Storer R Vessella PH Lange ML Disis 2000 Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer J Urol 164 1825 1829 11025777 1:CAS:528: DC%2BD3cXnslChsrY%3D
41. S Mosolits U Harmenberg U Ruden L Ohman B Nilsson B Wahren J Fagerberg H Mellstedt 1999 Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma Cancer Immunol Immunother 47 315 320 10203061 1:STN:280:DyaK1M3hslOisw%3D%3D (Pubitemid 29151830)
42. S Mosolits M Steinitz U Harmenberg U Ruden E Eriksson H Mellstedt J Fagerberg 2002 Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma Cancer Immunol Immunother 51 209 218 12012108 1:CAS:528:DC%2BD38XlsVKms7c%3D (Pubitemid 34493955)
43. KS Anderson J Wong A Vitonis CP Crum PM Sluss J Labaer D Cramer 2010 p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer Cancer Epidemiol Biomarkers Prev 19 859 868 20200435 1:CAS:528:DC%2BC3cXivFegt7w%3D
44. P Andreu M Johansson NI Affara F Pucci T Tan S Junankar L Korets J Lam D Tawfik DG DeNardo L Naldini KE de Visser M De Palma LM Coussens 2010 FcRgamma activation regulates inflammation-associated squamous carcinogenesis Cancer Cell 17 121 134 20138013 1:CAS:528:DC%2BC3cXlt1Kls70%3D
45. Calabrich A, Fernandes Gdos S, Katz A (2008) Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncology (Williston Park) 22, 1250-1258; discussion 1259, 1263
46. K Mehta C Osipo 2009 Trastuzumab resistance: role for Notch signaling Sci World J 9 1438 1448 1:CAS:528:DC%2BC3cXhtl2qtLw%3D
47. D Marx A Fattahi-Meibodi R Kudelka T Uebel W Kuhn H Meden 1998 Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma Anticancer Res 18 2891 2894 9713482 1:CAS:528: DyaK1cXlsF2qtbk%3D (Pubitemid 28388858)
48. C Streckfus L Bigler T Dellinger X Dai A Kingman JT Thigpen 2000 The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study Clin Cancer Res 6 2363 2370 10873088 1:CAS:528:DC%2BD3cXksVGhsLw%3D (Pubitemid 30399204)
49. L Maple R Lathrop S Bozich W Harman R Tacey M Kelley A Danilkovitch-Miagkova 2004 Development and validation of ELISA for herceptin detection in human serum J Immunol Methods 295 169 182 15627622 1:CAS:528:DC%2BD2MXotVCn (Pubitemid 41057779)
50. EY Lasfargues WG Coutinho ES Redfield 1978 Isolation of two human tumor epithelial cell lines from solid breast carcinomas J Natl Cancer Inst 61 967 978 212572 1:STN:280:DyaE1M%2FivFKlsQ%3D%3D (Pubitemid 9042085)
51. L Rivoltini M Carrabba V Huber C Castelli L Novellino P Dalerba R Mortarini G Arancia A Anichini S Fais G Parmiani 2002 Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction Immunol Rev 188 97 113 12445284 1:CAS:528:DC%2BD38Xps1Oqsrg%3D (Pubitemid 35398868)
52. Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, Chap. 3, Unit 3.22
53. S Neri E Mariani A Meneghetti L Cattini A Facchini 2001 Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants Clin Diagn Lab Immunol 8 1131 1135 11687452 1:CAS:528:DC%2BD3MXptVCqtr0%3D (Pubitemid 33035744)